Dr Pietro Canetta reflects on how the rapidly advancing field of IgA nephropathy research has transformed from limited ...

Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home ...

Dr Andrew Bomback comments on how disparities in access to healthcare significantly delay the diagnosis and treatment of IgA ...

IgA nephropathy is an autoimmune disease of the kidneys. It’s associated with several health conditions and is a significant contributor to chronic kidney disease and kidney failure. In the ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic ...

Haseeb Ahmad brings over 25 years of leadership experience in life sciences, most recently serving as President of Novartis ...

Travere Therapeutics' Filspari boosts revenue with FDA approval, but heavy losses and competitive threats raise concerns for ...

The company plans to present additional results at a medical meeting in 2025. Patients with IgA nephropathy (IgAN) (n=14) received subcutaneous doses of ARO-C3 (400 mg) on Days 1, 29, and 113 and ...

Immunoglobulin A nephropathy (also known as IgA nephropathy or Berger's disease) is a condition that causes IgA antibodies to accumulate in the kidneys—leading to damage that affects their blood ...

Select Phase 1/2 Study Results Patients with IgA nephropathy (IgAN) (n=14) received subcutaneous doses of ARO-C3 (400 mg) on Days 1, 29, and 113 and were followed through Day 169 Pharmacodynamic ...

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was ...

Beyond AMR, Biogen is planning to initiate phase 3 trials of felzartamab in two kidney diseases, IgA nephropathy and primary ...